Descripción de la empresa
Zai Lab Limited operates within the healthcare sector, specifically functioning as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of products targeting medical conditions in oncology, immunology, neuroscience, and infectious diseases. The company's commercial portfolio includes Zejula, an orally administered poly (ADP-ribose) product, which represents its current focus in product delivery and market engagement. In terms of scale, Zai Lab holds a market capitalization of $2.37B while generating annual revenue (TTM) of $460.16M and maintaining an employee base of 1784 individuals. These valuation and revenue figures position the company as a mid-cap biotechnology firm with significant operational reach, indicating a substantial footprint in a highly competitive industry where capital intensity and workforce size are critical for advancing multiple therapeutic pipelines simultaneously.
Salud financiera
The company reported a revenue (TTM) of $460.16M against a net income (TTM) of $-175,536,992, with an EBITDA of $-214,424,000, highlighting a significant disparity between top-line growth and bottom-line profitability. This substantial gap between revenue and net income reveals a cost structure characterized by high operating expenses typical of the biotechnology industry, where research and development costs heavily impact net earnings before any revenue is realized. The free cash flow stands at $-92,507,872, which indicates that the company is currently burning cash rather than generating liquidity, implying a reliance on external capital sources or existing cash reserves to fund ongoing operations and clinical trials. Analyzing the three primary margins shows a gross margin of 10.5%, suggesting a relatively low margin on sales before operating expenses, while the operating margin is -54.4% and the profit margin is -38.1%, reflecting intense cost pressures and a lack of net profitability. On the balance sheet, the company holds $689.57M in cash compared to $224.26M in debt, supported by a debt-to-equity ratio of 31.34, which suggests a leveraged position where equity capital is significantly higher than debt obligations. The current ratio of 2.45 indicates strong short-term liquidity, showing that the company possesses 2.45 times the assets necessary to cover its short-term liabilities, providing a buffer against immediate financial obligations. Furthermore, the return on equity is -22.6% and the return on assets is -12.2%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, a common characteristic for early-stage or growth-phase biotechnology firms focusing on R&D.
Evaluación de valoración
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -15.04, a divergence that implies the market is pricing in future earnings expectations that differ significantly from current performance, though the negative forward P/E still reflects the company's unprofitable status. The price-to-book ratio is 3.25, indicating that the stock trades at a significant premium of over three times its book value, which suggests investors are willing to pay more for the company's assets based on expectations of future product approvals or pipeline value. Alternative valuation metrics such as the price-to-sales ratio of 5.15 and the EV/EBITDA of -106.19 provide additional context, with the high P/S ratio suggesting the market values the company heavily relative to its sales volume despite the lack of profitability. The 52-week high is $44.34 and the 52-week low is $15.96, placing the current market dynamics within a wide trading range that reflects high volatility and potential for significant price swings relative to recent historical data. The beta value of 0.86 indicates that the stock's price volatility is slightly lower than the broader market, suggesting a moderate correlation with overall market movements rather than extreme sensitivity to general market fluctuations.
Growth & Income
Zai Lab Limited achieved a revenue growth (YoY) of 17.0%, while earnings growth (YoY) is N/A due to continued losses, indicating that top-line expansion is outpacing any potential for immediate profit recovery as the company scales its operations. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, however negative, are not distributed to shareholders but are instead reinvested into research, development, and commercialization efforts to drive future growth. This reinvestment strategy is typical for biotechnology companies that prioritize expanding their product pipeline and securing regulatory approvals over providing current income to investors. Overall, the growth and income profile is defined by strong revenue expansion coupled with a complete absence of dividend income, reflecting a capital-intensive growth model where shareholder returns are expected to materialize only after the company achieves commercial profitability.